3 results about "CD46" patented technology

The application discloses an enhanced CD46 decoy protein and application thereof in preparation of a medicine against bovine viral diarrhea virus, and belongs to the technical field of biological medicine. The application first analyzes the crystal structure of an E2-CD46 complex, determines key amino acid sites of a binding interface between E2 and CD46, and constructs a mutant with significantly improved affinity compared with a wild type. The application further constructs a dimer and a trimer with a CD46 truncated body or mutant as a monomer. The obtained high-affinity decoy proteins mCD46-12 and mCD46-13 can achieve nearly complete virus neutralization and blocking effect at micromolar concentration, can effectively competitively inhibit invasion of BVDV to host cells, provide a brand-new and efficient candidate molecule for preparation of a medicine for treating bovine viral diarrhea infection, and have great clinical application prospect and economic and social value.

This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and / or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.